Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)

By sjmartinez • September 6, 2024

Armstrong AW, Riedl E, Brunner PM, Piaserico S, Visser WI, Haustrup N, Konicek BW, Kadziola Z, Nunez M, Brnabic A, Schuster C. Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO). Acta Derm Venereol. 2024 Sep 5;104:adv40556. doi: 10.2340/actadv.v104.40556. PMID: 39235051.

Tags: Dermatology, Publications

Contact Dermatitis in the United States: A Population-Based Study on Patient Visit Characteristics and Treatment Prescription Patterns

Hao A, Yu RP, Kikuchi R, Sadrolashrafi K, Guo L, Yamamoto RK, Tolson H, Yee D, Bilimoria S, Pourali SP, Adler BL, Armstrong AW. Contact[...]

Radiation therapy for a case of poikilodermatous plaques in an otherwise healthy young man: A case report

Biba U, Poppens MJ, Collier EK, Cheng K. Radiation therapy for a case of poikilodermatous plaques in an otherwise healthy young man: A case report.[...]

Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer

Chow F, Lamoureux F, Moriceau G. Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer. Front Immunol. 2024 Sep 26;15:1487952. doi: 10.3389/fimmu.2024.1487952. PMID: 39391312; PMCID: PMC11464455.